Oncolytics Biotech Stock Analysis
| ONCY Stock | USD 1.06 0.02 1.92% |
Oncolytics Biotech is undervalued with Real Value of 2.58 and Target Price of 7.33. The main objective of Oncolytics Biotech stock analysis is to determine its intrinsic value, which is an estimate of what Oncolytics Biotech is worth, separate from its market price. There are two main types of Oncolytics Biotech's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Oncolytics Biotech's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Oncolytics Biotech's stock to identify patterns and trends that may indicate its future price movements.
The Oncolytics Biotech stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Oncolytics Biotech is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Oncolytics Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Oncolytics Biotech's ongoing operational relationships across important fundamental and technical indicators.
Oncolytics |
Oncolytics Stock Analysis Notes
The book value of the company was now reported as 0.37. The company recorded a loss per share of 0.3. Oncolytics Biotech last dividend was issued on the 25th of May 2018. The entity had 10:95 split on the 25th of May 2018. Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Oncolytics Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Oncolytics Biotech contact Dr MBA at 403 670 7377 or learn more at https://www.oncolyticsbiotech.com.Oncolytics Biotech Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Oncolytics Biotech's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Oncolytics Biotech or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Oncolytics Biotech generated a negative expected return over the last 90 days | |
| Oncolytics Biotech has high historical volatility and very poor performance | |
| Oncolytics Biotech has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (27.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oncolytics Biotech currently holds about 32.36 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Oncolytics Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from zacks.com: Gilead Gears Up to Report Q1 Earnings What to Expect |
Oncolytics Biotech Upcoming and Recent Events
Earnings reports are used by Oncolytics Biotech to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Oncolytics Biotech previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Oncolytics Largest EPS Surprises
Earnings surprises can significantly impact Oncolytics Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-11 | 2022-06-30 | -0.11 | -0.09 | 0.02 | 18 | ||
2020-11-11 | 2020-09-30 | -0.14 | -0.16 | -0.02 | 14 | ||
2023-05-05 | 2023-03-31 | -0.13 | -0.1 | 0.03 | 23 |
Oncolytics Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oncolytics Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oncolytics Biotech backward and forwards among themselves. Oncolytics Biotech's institutional investor refers to the entity that pools money to purchase Oncolytics Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bmo Capital Markets Corp. | 2023-12-31 | 37.6 K | Susquehanna International Group, Llp | 2023-12-31 | 30.3 K | Ausdal Financial Partners Inc | 2023-12-31 | 30 K | Brave Asset Management Inc | 2023-12-31 | 25 K | Two Sigma Securities, Llc | 2023-12-31 | 23.4 K | Newman Dignan & Sheerar Inc | 2023-12-31 | 22 K | Lpl Financial Corp | 2023-12-31 | 19.6 K | C2p Capital Advisory Group Llc Dba Prosperity Capital Advisors | 2023-12-31 | 15 K | Banque Cantonale Vaudoise | 2023-12-31 | 11.9 K | Anson Funds Management Lp | 2023-12-31 | 3.8 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 231.4 K |
Oncolytics Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 80.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Oncolytics Biotech's market, we take the total number of its shares issued and multiply it by Oncolytics Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Oncolytics Profitablity
Oncolytics Biotech's profitability indicators refer to fundamental financial ratios that showcase Oncolytics Biotech's ability to generate income relative to its revenue or operating costs. If, let's say, Oncolytics Biotech is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Oncolytics Biotech's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Oncolytics Biotech's profitability requires more research than a typical breakdown of Oncolytics Biotech's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.71) | (0.75) | |
| Return On Capital Employed | (0.98) | (1.03) | |
| Return On Assets | (0.71) | (0.75) | |
| Return On Equity | (1.01) | (0.96) |
Management Efficiency
Oncolytics Biotech has return on total asset (ROA) of (0.5547) % which means that it has lost $0.5547 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0266) %, meaning that it created substantial loss on money invested by shareholders. Oncolytics Biotech's management efficiency ratios could be used to measure how well Oncolytics Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.75 in 2024. Return On Capital Employed is likely to drop to -1.03 in 2024. At this time, Oncolytics Biotech's Other Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 32 M in 2024, whereas Total Assets are likely to drop slightly above 30.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.41 | 0.39 | |
| Net Current Asset Value | 28.7 M | 25.5 M | |
| Tangible Asset Value | 29.6 M | 26.3 M | |
| Tangible Book Value Per Share | 0.41 | 0.39 | |
| Enterprise Value Over EBITDA | (2.61) | (2.74) | |
| Price Book Value Ratio | 4.29 | 4.50 | |
| Enterprise Value Multiple | (2.61) | (2.74) | |
| Price Fair Value | 4.29 | 4.50 | |
| Enterprise Value | 87.1 M | 118.3 M |
The analysis of Oncolytics Biotech's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Oncolytics Biotech's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Oncolytics Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 1.46 |
Technical Drivers
As of the 24th of April, Oncolytics Biotech holds the Variance of 25.86, coefficient of variation of (7,227), and Risk Adjusted Performance of 1.0E-4. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oncolytics Biotech, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down thirteen technical drivers for Oncolytics Biotech, which can be compared to its competitors. Please check Oncolytics Biotech mean deviation and maximum drawdown to decide if Oncolytics Biotech is priced some-what accurately, providing market reflects its current price of 1.06 per share. Given that Oncolytics Biotech is a hitting penny stock territory we advise to closely look at its jensen alpha.Oncolytics Biotech Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Oncolytics Biotech middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Oncolytics Biotech. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Oncolytics Biotech Predictive Daily Indicators
Oncolytics Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Oncolytics Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Oncolytics Biotech Forecast Models
Oncolytics Biotech's time-series forecasting models are one of many Oncolytics Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oncolytics Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Oncolytics Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Oncolytics Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Oncolytics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Oncolytics Biotech. By using and applying Oncolytics Stock analysis, traders can create a robust methodology for identifying Oncolytics entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (6.74) | (7.08) | |
| Operating Profit Margin | (6.81) | (7.15) | |
| Net Loss | (6.75) | (7.08) | |
| Gross Profit Margin | 0.00 | 0.00 |
Current Oncolytics Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Oncolytics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Oncolytics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 7.33 | Strong Buy | 7 | Odds |
Most Oncolytics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Oncolytics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Oncolytics Biotech, talking to its executives and customers, or listening to Oncolytics conference calls.
Oncolytics Stock Analysis Indicators
Oncolytics Biotech stock analysis indicators help investors evaluate how Oncolytics Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Oncolytics Biotech shares will generate the highest return on investment. By understating and applying Oncolytics Biotech stock analysis, traders can identify Oncolytics Biotech position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 9.5 M | |
| Common Stock Shares Outstanding | 67.6 M | |
| Total Stockholder Equity | 27.6 M | |
| Tax Provision | 111 K | |
| Property Plant And Equipment Net | 647 K | |
| Cash And Short Term Investments | 34.9 M | |
| Cash | 31.5 M | |
| Accounts Payable | 1.1 M | |
| Net Debt | -31.1 M | |
| 50 Day M A | 1.0648 | |
| Total Current Liabilities | 4.2 M | |
| Other Operating Expenses | 33.8 M | |
| Non Current Assets Total | 647 K | |
| Non Currrent Assets Other | -1.00 | |
| Stock Based Compensation | 2.1 M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.Note that the Oncolytics Biotech information on this page should be used as a complementary analysis to other Oncolytics Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Oncolytics Stock analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Oncolytics Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncolytics Biotech. If investors know Oncolytics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncolytics Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.30) | Return On Assets (0.55) | Return On Equity (1.03) |
The market value of Oncolytics Biotech is measured differently than its book value, which is the value of Oncolytics that is recorded on the company's balance sheet. Investors also form their own opinion of Oncolytics Biotech's value that differs from its market value or its book value, called intrinsic value, which is Oncolytics Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncolytics Biotech's market value can be influenced by many factors that don't directly affect Oncolytics Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.